Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 8/20 | 0.54 |
| ▸ | CTSK | P43235 | 7/20 | 0.54 |
| ▸ | ACE | P12821 | 2/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 3/20 | 0.49 |
| ▸ | PPARA | Q07869 | 5/20 | 0.49 |
| ▸ | PPARG | P37231 | 4/20 | 0.49 |
| ▸ | PPARD | Q03181 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6495441 | 0.91 | TACR1 (0.51) | CTSSCTSKACESCN9ACTSL | |
| SCHEMBL18428007 | 0.85 | ATM (0.46) | CTSSCTSKACECTSLPPARA | |
| SCHEMBL613640 | 0.82 | CTSS (0.76) | CTSSCTSKACESCN9ACTSL | |
| SCHEMBL4122289 | 0.82 | CTSS (0.76) | CTSSCTSKACESCN9ACTSL | |
| SCHEMBL4600435 | 0.82 | CTSS (0.76) | CTSSCTSKACESCN9ACTSL | |
| SCHEMBL29401990 | 0.82 | CTSS (0.76) | CTSSCTSKACESCN9ACTSL | |
| SCHEMBL6503900 | 0.82 | CTSS (0.52) | CTSSCTSKCTSLCTSBPTPN1 | |
| SCHEMBL7059635 | 0.82 | ERAP2 (0.48) | ACEPTPN1ITGB3ITGA2BTACR1 | |
| SCHEMBL17912391 | 0.81 | CTSS (0.57) | CTSSCTSKACESCN9ACTSL | |
| SCHEMBL17912388 | 0.81 | CTSS (0.57) | CTSSCTSKACESCN9ACTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6972340-B2 | Selective protein tyrosine phosphatatase inhibitors | ABBOTT LABORATORIES (US) | 2005-12-06 | — | — | US | disclosed |
| WO-2003072537-A2 | SELECTIVE PROTEIN TYROSINE PHOSPHATATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003020688-A1 | SELECTIVE PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2003-03-13 | — | — | WO | disclosed |
| US-20020169157-A1 | Selective protein tyrosine phosphatatase inhibitors | ABBOTT LABORATORIES | 2002-11-14 | — | — | US | disclosed |
| US-20020072516-A1 | Selective protein tyrosine phosphatatase inhibitors | ABBVIE INC. | 2002-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169157-A1 | Selective protein tyrosine phosphatatase inhibitors | PPM1B, PPM1A, PPM1D | CTSS 2380/4885CTSK 2543/4885ACE 1661/4885 |
| US-20020072516-A1 | Selective protein tyrosine phosphatatase inhibitors | PPM1B, PPM1A, PPM1D | CTSS 2380/4885CTSK 2543/4885ACE 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.